Table 2.

Summary of adverse events

	Dose-escalation cohort, n = 11 (%)	Dose-expansion cohort, n = 16 (%)	RP2/3D cohort, N = 22 (%)	Total, N = 27 (%)
Any AE	11 (100)	15 (94)	21 (95)	26 (96)
Drug-related AE	9 (82)	13 (81)	18 (82)	22 (81)
Grade ≥3 AE	9 (82)	13 (81)	18 (82)	22 (81)
Drug-related grade ≥3 AE	6 (55)	5 (31)	8 (36)	11 (41)
Serious AE	8 (73)	9 (56)	12 (55)	17 (63)
Drug-related serious AE	3 (27)	1 (6)	2 (9)	4 (15)
AEs resulting in drug discontinuation	3 (27)	2 (13)	3 (14)	5 (19)
On-study deaths	0	1 (6)	1 (5)	1 (4)